Additionally, dieckol was found to dose-dependently upregulate the expression of Bid and Bim pro-apoptotic proteins in Hep3B hepatocarcinoma cells [130] and to downregulate the expression of the XIAP, FLIP and Bcl-2 anti-apoptotic proteins in SKOV3 ovarian cancer cells [114], while in MCF-7 breast cancer cells, the treatment with eckstolonol caused a dose-dependent downregulation of the anti-apoptotic protein Bcl-2 along with the upregulation of the pro-apoptotic protein Bax and tumor suppressor p53 [132]. Here, BCL2 is linked to ovarian cancer.